Related Experiment Video

Updated: Jun 27, 2025

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
14:28

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care

Published on: May 10, 2024

1.5K

Organ-Dysfunction Markers in Mild-to-Moderate COVID-19 Convalescents

Aleksandra Wiśniewska1, Aleksandra Kijak1, Karolina Nowak1

  • 1Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.

Journal of Clinical Medicine
|April 27, 2024
PubMed

Insights

Mild COVID-19 survivors show no increased risk of lung fibrosis or kidney disease six months post-recovery. However, regular check-ups are advised for early detection of potential long COVID complications.

Area of Science:

  • Cardiovascular and Respiratory Science
  • Nephrology
  • Neurology

Background:

  • The COVID-19 pandemic has led to long-term health issues, termed long COVID, affecting multiple organ systems.
  • Understanding the persistent effects of mild-to-moderate COVID-19 on organ function is crucial for public health.
  • This study investigates potential long-term sequelae in recovered individuals.

Purpose of the Study:

  • To evaluate the risk of respiratory, cardiovascular, neural, and renal system dysfunction in individuals with a history of mild-to-moderate COVID-19.
  • To compare organ system markers in recovered COVID-19 patients (convalescents) with healthy controls at least six months post-infection.

Main Methods:

  • A cohort of 294 healthy blood donors was analyzed, comprising 215 COVID-19 convalescents and 79 never-infected controls.
  • Biomarkers including soluble CD163, TGF-beta, Lp-PLA2, NCAM-1, S100, NGAL, and creatinine were measured.
  • Statistical significance was determined using a p-value < 0.05.

Main Results:

  • Significant differences were observed in Lp-PLA2, S100, and NCAM-1 levels between convalescents and controls.
  • Lp-PLA2 and NCAM-1 levels were lower in the convalescent group compared to the control group.
  • S100 levels were found to be higher in convalescents than in healthy controls.

Conclusions:

  • Mild-to-moderate COVID-19 convalescents appear to have a low risk of developing lung fibrosis or chronic kidney disease.
  • Despite low risk, continued prophylactic examinations are recommended for early detection of any adverse COVID-19 outcomes.
  • Further research may be needed to fully understand the long-term neurological and cardiovascular implications.

Keywords:
COVID-19long COVIDlung fibrosisneurodegenerationrenal function

More Related Videos

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-1906:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.3K
Immunostaining-Based Detection of Dynamic Alterations in Red Blood Cell Proteins10:07

Immunostaining-Based Detection of Dynamic Alterations in Red Blood Cell Proteins

Published on: March 17, 2023

2.0K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
144
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
265
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
204
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
261